Almirall and the Spanish Pharmacology Society confer the pharmacology award 2007

·The award encourages research in the pharmacological area and is given out during the Spanish Pharmacology Society Congress

·The €9,000 award goes to Dr Marta Alegret for the project “Effect of proatherogenic and/or inflammatory stimulae on gene expression related to familial combined hyperlipidemia”

Barcelona, 20 September 2007.- The Pharmacology Award2007 was given out yesterday during the 29^th Spanish Pharmacology Congress held in Alcalá de Henares (Madrid) from 17 to 19 September. Promoted jointly by Almirall and the Spanish Pharmacology Society, this award is the only one to acknowledge the quality of a future research project within the Pharmacology field in Spain rather than an already completed study.

During this year’s congress the award, consisting of €9,000, was given to Dr Marta Alegret, from the University of Barcelona for the project: “Effect of proatherogenic and/or inflammatory stimulae on gene expression related to familial combined hyperlipidemia”. The project will be conducted during the period 2007-2008 and its results presented at the next Spanish Pharmacology Society Congress in 2008.

The jury is made up of Dr Francisco Zaragozá, President of the Spanish Pharmacology Society and doctors Jesús Llenas and Amadeu Gavaldà, from Almirall. Works were assessed through an independent scoring process and later on through jury consensus. According to Dr Llenas: “The winning project was chosen by contemplating how it might contribute to the current pharmacological panorama, its originality, structure and the potential novelty of its results. Dr Alegret’s project met all these conditions by focusing on the important disease combined hyperlipidemia, which is the disorder mostly responsible for fatal ischemic cardiopathy”.

Results of the Pharmacology Award 2006 were made public during the event.

Almirall

Almirall, an international pharmaceutical company committed to health headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and quality of life.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.

More information:

Ketchum/SEIS

Victoria Hernández / Sonia San Segundo

sonia.sansegundo@ketchum.com

Tel.: 91 788 32 00